Conference call interim report

Invitation to attend Vitrolife’s conference call regarding presentation of the
interim report for the period January - March 2014. The presentation will be
held in English.
Time: Wednesday, April 23, 2014 at 10.00 a.m. CET.


Registration can preferably be done in advance under the following link:

https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=190307

or shortly before time of the conference starts on:

Sweden dial in number: +46 (0)8 5052 01 10
UK dial in number: +44 (0)20 7162 0077
Conference name: Vitrolife, conference ID: 944026

Vitrolife participants:
Thomas Axelsson, CEO
Mikael Engblom, CFO
The press release for Vitrolife’s interim report will be released at 8.30 CET on
the same day.
Before the conference call, slides will be available at the company web page,
http://www.vitrolife.com/en/Corporate/

A recorded version of the presentation will be available for seven days on
number

+46 (0)8 5052 0333 (Sweden) or 020 7031 4064 (UK), access code 944026.

Gothenburg, April 16, 2014
VITROLIFE AB (publ)
Contact:
Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on April
16, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/